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Abstract
Introduction: Fatigue is a known symptom of advanced lung disease and impacts quality of life and psychological health. Many 
of these patients undergo pulmonary rehabilitation as part of their therapy. Understanding the effect of pulmonary rehabilitation 
on fatigue in these patients is important, as one may be able to design more focused rehabilitation programs.
The aim of this study is to evaluate the effect of pulmonary rehabilitation on fatigue as measured by the Fatigue Severity Scale 
(FSS) in patients with advanced lung disease.
Material and methods: Patients were enrolled in a standardized 6 week pulmonary rehabilitation program. They were asked to 
complete questionnaires to evaluate their self-reported fatigue (FSS), and depression as measured by Geriatric Depression Scale 
(GDS). The GDS is a self-reported assessment tool used to identify depression in patients. The FSS is a validated instrument that 
indicates a perception of fatigue that might require medical intervention. Participants completed questionnaires both at baseline 
and after completing the standardized pulmonary rehabilitation program. Data was analyzed in Statistical Analysis System (SAS). 
The change in FSS was evaluated using the Wilcoxon signed-rank test. P-values < 0.05 were considered statistically significant.
Results: 21 patients (12 females; 9 males; mean age 64.3 ± 11.2 yrs) were considered for the study. Pre-pulmonary rehabili-
tation FSS scores ranged from 1.6 to 6.7 (mean score of 4.6 ± 1.7). Post pulmonary rehabilitation FSS scores ranged 1.0 to 6.2 
(mean score of 3.9 ± 1.6). The median pre-rehabilitation FSS was 5.3 (inter quartile range; Q1–Q3: 3.0–6.1), and median post 
rehabilitation FSS was 3.9 (inter quartile range; Q1–Q3: 2.6–5.1). There was a significant decrease in FSS scores after completing 
pulmonary rehabilitation program (p < 0.0208). There was a decrease in GDS (pre-rehabilitation, mean: 5.5 ± 3.6; post-rehabili-
tation, mean: 4.2 ± 2.9), but this decrease was not statistically significant. The change in GDS correlated with the change in FSS 
(Spearman Correlation Coefficient 0.525, p < 0.0146).
Conclusions: Patients with advanced lung disease reported a measurable component of fatigue. Participating in pulmonary reha-
bilitation resulted in significant improvement in patient’s self-reported fatigue severity. Further studies are necessary to evaluate 
and design interventions to improve fatigue in in the setting of advanced lung disease.
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Streszczenie
Wstęp: Zmęczenie jest dobrze znanym objawem zaawansowanej choroby płuc. Ma ona znaczący wpływ na jakość życia i zdro-
wie psychiczne pacjenta, dlatego wielu pacjentów w ramach terapii przechodzi rehabilitację oddechową. Aby stworzyć nowe 
ukierunkowane programy rehabilitacyjne bardzo istotne jest zrozumienie wpływu rehabilitacji oddechowej na nasilenie duszności 
u tych chorych.
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Celem pracy jest ocena wpływu rehabilitacji oddechowej na nasilenie zmęczenia mierzonego za pomocą Fatigue Severity Scale 
(FSS) u pacjentów z zaawansowaną chorobą płuc.
Materiał i metody: Pacjenci zakwalifikowani do standardowego 6-tygodniowego programu rehabilitacyjnego byli proszeni o do-
kładne wypełnienie 2 ankiet przed rehabilitacją i po jej zakończeniu: ankiety FSS, która jest cennym narzędziem pozwalającym na 
ocenę zmęczenia pod kątem potrzeby interwencji medycznej, oraz ankiety Geriatric Depression Scale (GDS), która jest narzędziem 
używanym do oceny nasilenia depresji przez samych pacjentów. Dane przeanalizowano za pomocą programu Statistical Analysis 
System (SAS). Zmienne wartości FSS oceniono przy użyciu testu Wilcoxona dla par obserwacji. Wartości p < 0,05 uznano za 
istotne statystycznie.
Wyniki: Do badania włączono 21 pacjentów (12 kobiet i 9 mężczyzn, średnia wieku 64,3 ± 11,2 roku). Wyniki FSS przed rehabi-
litacją wynosiły od 1,6 do 6,7 (średni wynik na poziomie 4,6 ± 1,7), a po rehabilitacji od 1,0 do 6,2 (średni wynik na poziomie 3,9 
± 1,6). Mediana FSS przed rehabilitacją wynosiła 5,3 (przedział międzykwartylowy; Q1–Q3: 3,0–6,1), po rehabilitacji wyniosła 
3,9 (przedział międzykwartylowy; Q1–Q3: 2,6–5,1). Wykazano istotnie statystycznie niższy wynik w FSS po zakończeniu programu 
rehabilitacji oddechowej (p < 0,0208; test Wilcoxona dla par obserwacji). Wykazano również niższy wynik w GDS po rehabilitacji, 
ale nie był on istotny statystycznie (średnia przed rehabilitacją: 5,5 ± 3,6; średnia po rehabilitacji: 4,2 ± 2,9). Zmiany w GDS 
korelowały ze zmianami w FSS (współczynnik korelacji rang Spearmana 0,525, p < 0,0146).
Wnioski: U chorych z zaawansowaną chorobą płuc nasilenie zmęczenia można przedstawić za pomocą mierzalnych danych. 
U pacjentów, którzy przeszli program rehabilitacji oddechowej, stwierdzono istotną poprawę w postaci zmniejszenia nasilenia 
zmęczenia. Potrzebne są dalsze badania, aby oceniać nowe metody leczenia, które pozwolą zmniejszyć dolegliwości towarzyszące 
zaawansowanym chorobom płuc.
Słowa kluczowe: rehabilitacja oddechowa, zmęczenie, depresja, narzędzia przesiewowe, POChP, choroby śródmiąższowe płuc
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Introduction
Fatigue is defined as extreme, persistent tiredness 
and mental, physical weakness or exhaustion [1]. 
It is a known symptom of advanced lung diseases 
that impacts quality of life and psychological 
health [2]. There is a general impression that 
features of fatigue manifest as underlying depres-
sion [3] however, each differ and may represent 
different aspects of underlying psychological 
impairment. Measurement of fatigue has been 
utilized in many neurological [4] and rheumato-
logical [5] disorders but has yet to gain popularity 
in pulmonary medicine. 
Patients with advanced lung disease such as 
chronic obstructive pulmonary disease (COPD), 
interstitial lung disease (ILD) and other debilita-
ting pulmonary conditions face symptomatology 
consistent with oxygen deprivation, including 
dyspnea, cough, wheezing and exercise intoleran-
ce. These patients regularly undergo pulmonary 
rehabilitation as part of their therapy [2, 6]. Ratio-
nal for using pulmonary rehabilitation as an adju-
vant to pharmacotherapy is well established [7]. 
However, understanding the effects of pulmonary 
rehabilitation on fatigue in these patients is not 
well studied but is very important, as one may 
be able to design more structured rehabilitation 
programs targeting fatigue improvement as well 
as exercise capacity which set the basis for this 
study. We decided to study the effects of pulmo-
nary rehabilitation on fatigue as measured by 
the Fatigue Severity Scale (FSS) in patients with 
advanced lung disease. 
Pulmonary rehabilitation
The American Thoracic Society and the Euro-
pean Respiratory Society (ATS/ERS) have defined 
pulmonary rehabilitation (PR) as an “evidence 
based, multidisciplinary and comprehensive 
intervention for patient with chronic respiratory 
diseases who are symptomatic and often have 
decreased daily life activities” [7]. The principal 
purpose of PR programs is to improve function, 
disease related symptoms, optimize functional 
capacity and an overall improvement in quality of 
life (QoL). Pulmonary rehabilitation has become 
a staple of therapy in advanced lung disease in-
cluding COPD [8], idiopathic pulmonary fibrosis 
[9] and pulmonary hypertension [10] amongst 
others. It is also well known that participation 
in a pulmonary rehabilitation program reduces 
the number of future exacerbations in COPD 
patients [11].
The PR program at our center is certified by 
the American Association of Cardiovascular and 
Pulmonary Rehabilitation (AACVPR) and is de-
signed towards adult patients with chronic lung 
disease or patients preparing/recovering from 
lung surgery. The program consists of an exercise 
and education component with 3 sessions weekly 
over a period of 6–8 weeks. Following the com-
pletion of the 6–8 week program, maintenance 
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sessions are also available for patients to partic-
ipate. The rehab facility at our site is equipped 
with exercise equipment such as treadmill, upper/ 
/lower body recumbent stepper (NuStep® Inc., 
Ann Arbor MI USA), arm ergometers and free 
weights. In addition, safety equipments available 
include: ECG monitoring, pulse oximetry, blood 
pressure monitoring and supplemental oxygen. 
The education component consists of bi-weekly 
educational lecture series that comprise of breath-
ing techniques along with stress and relaxation 
exercises. As part of our PR program all patients 
are asked to fill out quality of life, fatigue and 
sleep questionnaires before and after completion 
of the program.
Measuring fatigue and depression
As there is a general impression that features 
of fatigue manifest as underlying depression [3] it 
is important to define and quantitatively measure 
these two separate domains. To better understand 
and quantify fatigue severity many scales have 
been developed [12]. The most commonly used 
fatigue scale is the Fatigue Severity Scale (FSS) 
developed by Krupp et al. [4]. The FSS is a 9 
question validated instrument that indicates a 
perception of fatigue that might require medical 
intervention [4] and is scored using a 7-point 
Likert scale where a score of 7 is associated with 
greater amounts of fatigue. The sum of responses 
is taken and divided by number of items for the 
scale score. The mean score for normal individ-
uals on the FSS is 2.3 ± 0.7 [13]. 
In addition to fatigue, depression symptom-
atology was also evaluated using the Geriatric 
Depression Scale (GDS). The GDS short form 
is a self reported assessment tool which was 
used to identify depression in patients; a score 
greater than 5 is considered suggestive of de-
pression [14, 15]. 
The GDS is a self-reported depression scale 
developed in 1982, specifically for the geriatric 
population (> 60 years) with time frame of “past 
week” [15]. It is used for screening depression in 
elderly population and therefore distinguishing 
dementia from depression in patients aged 65–85 
[14]. Items in the scale address cognitive and af-
fective domains while somatic domains are not 
addressed [14]. While the scale was originally 
developed as 30-item scale, the GDS has been 
modified (15 questions) and validated [16]. Both 
versions of the scale, GDS are answered in a “yes” 
or “no” fashion with 1 point assigned to items 
answered “yes” [14]. A GDS ≥ 11 is considered 
a sign for possible depression [14]. A 5 item GDS 
is also found to be equally effective as compared 
to 15 item GDS with a sensitivity of 0.94 and 
specificity of 0.81 respectively [16].
Material and methods
We conducted a retrospective review of data 
collected on 21 patients with diagnosis of advan-
ced lung disease who participated in the North 
Shore — Long Island Jewish Health System PR 
program. For the purposes of the study, COPD and 
IPF were defined using the standards established 
by the American Thoracic Society [9, 17]. At the 
time of the enrollment in PR, all patients were cli-
nically stable, and all were receiving optimal me-
dical therapy. All participants completed fatigue 
and depression questionnaires both at baseline 
and after completing the standardized pulmona-
ry rehabilitation program. Institutional Review 
Board approval was obtained. Data was analyzed 
using SAS (Cary, NC USA). The change in FSS 
was evaluated using the Wilcoxon signed-rank 
test. A p-value of ≤ 0.05 was considered statisti-
cally significant. 
All patients underwent complete pulmona-
ry function testing with body plethysmography 
(Care Fusion, Palm Springs, CA). From the spi-
rometry tracing, FEV1, FVC, and FEV1/FVC were 
calculated according to American Thoracic So-
ciety recommendations [18]. The results were 
expressed as absolute values and as percentages 
of the predicted value [19]. In addition lung vo-
lumes and diffusion capacity of carbon monoxide 
(DLco) was conducted. Reference values used 
for spirometry were from National Health and 
Nutrition Examination Survey (NHANES) III and 
DLco was calculated using Burrows formula. As 
part of standard of care, patients with ILD/IPF 
underwent a six minute walk test (6MWT) in 
accordance with ATS guidelines [20].
Results
Twenty one patients (12 females; 9 males; 
mean age 64.5 ± 10.9 yrs: 15 COPD, 5 ILD/IPF, 1 
other; Tab. 1) were considered for the study. For 
all patients oxygen saturation ranged between 88 
and 98 percent. Out of 21 patients 5 were on oxy-
gen therapy. Overall pulmonary function testing 
in COPD patients displayed a reduced FEV1/FVC 
ratio (0.58 ± 0.15) and increased residual vol-
ume (3.09 ± 1.04; Tab. 2). Patients with ILD/IPF 
showed a characteristically reduced diffusion 
capacity (DLCO) (14.32 ± 7.22) and slightly re-
Arunabh Talwar et al., Effects of pulmonary rehabilitation on Fatigue Severity Scale in patients with lung disease
537www.pneumonologia.viamedica.pl
Table 1. Patients — demographics
Diagnosis
No (%)
Sex COPD ILD/IPF Other Total
Male 5 
(23.8)
3 
(14.29)
1 
(4.7)
9 
(42.8)
Female 10 
(47.6)
2 
(9.52)
0 
(0.0)
12 
(57.4)
Total 15 
(71.43)
5 
(23.81)
1 
(4.76)
21 
(100.0)
Table 2. Pulmonary function testing results (means ± SD) of COPD patients (n = 15)
Spirometry Reference Actual measure Predicted percent of reference
FVC (L) 3.11 ± 0.62 1.82 ± 0.60 58.2 ± 13.79
FEV1 (L) 2.40 ± 0.46 1.09 ± 0.56 45.13 ± 20.2
FEV1/FVC% – 0.57 ± 0.15 –
FEF25–75% (L/sec) 2.30 ± 0.53 0.63 ± 0.46 28.93 ± 22.38
Lung volumes
TLC (L) 5.32 ± 0.87 5.30 ± 1.67 96.86 ± 20.97
RV (L) 2.09 ± 0.27 3.09 ± 1.03 149.20 ± 52.93
Diffusing capacity
DLCO [mL/mm Hg/mm] 22.45 ± 4.65 10.48 ± 5.07 46.33 ± 17.25
duced total lung capacity (64.8 ± 13.84; Tab. 3). 
Mean distance on 6MWT for these patients was 
320 meters. 
At baseline, pre-pulmonary rehabilitation 
FSS scores ranged from 1.6 to 6.7 [median score 
5.3 25th percentile (Q1)–75th percentile (Q3): 3.0–
6.1; mean score ± standard deviation: 4.6 ± 1.7] 
and post-rehabilitation FSS scores ranged 1.0 to 
6.2 (median score 3.9; Q1–Q3: 2.6–5.1; mean score 
Table 3. Pulmonary function testing results (means ± SD) of ILD/IPF patients (n = 5)
Spirometry Reference Actual measure Predicted percent of reference
FVC (L) 3.60 ± 1.35 2.98 ± 0.57 63.6 ± 14.77
FEV1 (L) 2.87 ± 0.98 2.43 ± 0.32 66 ± 13.11
FEV1/FVC (%) – 0.82 ± 0.06 –
Lung volumes
TLC (L) 5.65 ± 1.79 5.01 ± 0.47 64.8 ± 13.85
RV (L) 1.91 ± 0.53 1.79 ± 0.22 64.5 ± 20.14
Diffusing capacity
DLCO [mL/mm Hg/mm] 27.0 ± 3.80 14.32 ± 7.22 41.25 ± 3.69
of 3.9 ± 1.6). The change in FSS score after pul-
monary rehabilitation was statistically significant 
(p < 0.0208, Wilcoxon signed-rank test; Fig. 1). 
The COPD cohort had a pre-PR FSS score of 4.4 
± 1.7 and a post-PR FSS score of 4.1 ± 1.6 while 
the ILD/IPF cohort had a pre-PR FSS score of 5.0 
± 1.8 and a post-PR FSS score of 3.5 ± 1.8.
GDS scores at baseline, pre-rehabilitation 
showed a median score 4.0 (Q1–Q3: 3.0–9.0; mean 
5.5 ± 3.6) and a post-rehabilitation the median 
score of 4.0 (Q1–Q3: 2.0–6.0; mean 4.2 ± 2.9). 
Though there was improvement, the change was 
not statistically significant (p < 0.1492, Wilcoxon 
signed-rank test; Fig. 2). However, the change in 
GDS correlated with the change in FSS (Spearman 
Correlation Coefficient 0.525, p < 0.0146). The 
COPD cohort had a pre-PR GDS score of 5.5 ± 4.0 
and a post-PR GDS score of 4.0 ± 3.2 while the 
ILD/IPF cohort had a pre-PR GDS score of 4.6 ± 
2.5 and a post-PR GDS score of 4.6 ± 2.4.
Despite improvement in both fatigue and 
depression scores, improvement in 6MWT was 
not observed in these patients. 
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Figure 1. Effects of pulmonary rehabilitation on Fatigue Severity 
Scale
Figure 2. Effects of pulmonary rehabilitation on Geriatric Depression 
Scale
Figure 3. Multifactorial nature of fatigue
Discussion
Fatigue is defined as extreme, persistent 
tiredness and mental, physical weakness or 
exhaustion [1, 4, 5]. Although it has been studied 
in COPD [21, 22], there exists a paucity of data 
in other advanced diseases lung in general. Our 
retrospective study shows that in patients with 
severe lung disease there exists above normal 
levels of fatigue as measured by the FSS. In our 
study, in addition to fatigue a high GDS score was 
also common amongst these patients signifying 
presence of underlying depression. After partici-
pation in a structured PR program, not only did 
fatigue symptoms improve but there was a slight 
improvement in depression as well. The change 
in fatigue symptoms as per FSS after participation 
in PR was statistically significant (p < 0.0208, 
Wilcoxon signed-rank test). However, the change 
in depression symptoms as per GDS was not si-
gnificant (p < 0.1492, Wilcoxon signed-rank test). 
This shows that the change in FSS symptoms 
after PR is independent of change in depression 
symptomatology. This observation was similar 
across both COPD and ILD/IPF groups. 
Fatigue may be multifactorial in nature and is 
reported in many conditions such as deconditio-
ning, depression, muscle weakness, obstructive 
sleep apnea, osteoporosis, cardiac manifestation 
and medications as well. These factors should 
be individually assessed and treated for as they 
might all contribute to a feeling of fatigue (Fig. 3). 
Quantitative measurement of fatigue in other 
diseases has relied heavily on patient self reported 
fatigue questionnaires which used a 1–5 Likert 
scale system [23]. The Fatigue Severity Scale was 
originally described by Krupp et al. [4] and was 
studied in patients with multiple sclerosis and 
systemic lupus erythematosus (SLE). The FSS has 
been further validated [24] and has also been uti-
lized in other diseases such as hepatitis C [25] and 
Parkinson’s disease [26] where fatigue is one of 
the most commonly reported symptoms. Fatigue 
is routinely measured in COPD using the St. Geo-
rge’s and Chronic Respiratory questionnaires [27], 
however the FSS scale has not been widely uti-
lized. Fatigue in COPD has also been associated 
with reduced quality of life in moderate to seve-
re disease using the Multidimensional Fatigue 
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Inventory [28]. This is important to recognize 
as there exists a strong relationship between re-
spiratory symptoms and fatigue [29]. Fatigue has 
been reported to have a strong, direct and negative 
effect on functional performance [30] and per se 
will affect physiologic tests such as a six-minute 
walk testing. To the best of our knowledge this is 
the first study to utilize the Fatigue Severity Scale 
to study fatigue across a multifaceted advanced 
lung disease population. 
In addition, despite fatigue being one of the 
most commonly reported symptoms in ILD [31] 
there exists a paucity of data on self-reported fatigue. 
Patients with a diagnosis of ILD are often treated with 
pulmonary rehabilitation according to ATS guide-
lines [9]. Our study was able to demonstrate that 
PR improves fatigue in the ILD/IPF cohort as well. 
Our study showed that patients that partici-
pate in a pulmonary rehabilitation program will 
experience improvement in their fatigue symp-
toms as well as depressive symptoms. We also 
believe that fatigue represents as an independent 
therapeutic endpoint measurement in the advan-
ced lung disease patient population. This study 
lays the framework for understanding the rela-
tionship between fatigue and QoL. We do know 
that QoL is improved after patients participate in 
pulmonary rehabilitation [32]. If this effect is in 
part contributed by improvement in fatigue needs 
yet to be explained by further prospective studies. 
Conclusions
Patients with advanced lung disease reported 
a measurable component of fatigue and partici-
pating in a pulmonary rehabilitation program re-
sulted in significant improvement in the patients’ 
self reported fatigue severity. Our results suggest 
that fatigue and depression are two different do-
mains of psychosomatic impairment that can be 
objectively measured. Further prospective studies 
with a larger patient population are necessary to 
evaluate and design interventional programs to 
address fatigue as a possible therapeutic endpoint 
in the setting of advanced lung disease.
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